Oncology /Immuno-oncology Platform
Non-Human Primates Platform
Inflammation/Autoimmune Diseases Model
Metabolic/Liver/Cardiovascular Diseases Model
Antibody Screening Platform
Sepsis is a systemic inflammatory response syndrome (SIRS) caused by infection. It is clinically proven that there are bacteria or highly suspicious infection foci. Although sepsis is caused by infection, once it occurs its occurrence and development follow its own pathological processes, so sepsis can be considered a bodily response to infectious factors.
The incidence of sepsis is high. There are more than 18 million severe sepsis cases globally every year. There are approximately 750,000 sepsis cases in the United States every year, and the number is rising at a rate of 1.5%-8.0% annually. Sepsis is a dangerous disease with a high mortality rate. About 14,000 people die globally from complications of sepsis every day, and sepsis kills about 215,000 people annually in the United States. Despite considerable advances in anti-infective treatment and organ support techniques, the mortality rate of sepsis is still as high as 30%-70%. PharmaLegacy has established a Lipopolysaccharide (LPS)-induced sepsis model to support drug development for sepsis treatments. The application of the LPS bacterial endotoxin induces pathological reactions in mice similar to those seen in human sepsis. It is a commonly used method to establish animal models of sepsis.
Aim: To evaluate the efficacy of Dexamethasone as reference drug in CLP induced sepsis in mice. Observe the survival rate for one week.
Animal: C57BL/6, male
Reagent: Dexamethasone (Dex)
CLP induced Sepsis in C57BL/6 mice
Aim: To evaluate the efficacy of test articles in CLP induced sepsis in mice. To test actue cytokine change 24 hours after CLP surgery.
Animal: C57BL/6, male, 20-25 g, purchased from Shanghai SLAC Laboratory Animal Co. Ltd.
Reagent: Dexamethasone (Dex), Sinopharm Chemical Reagent Co., Ltd